title: Treatment outcome and prognostic factors for primary nasal lymphoma.
abstract: OBJECTIVE
  To report our experience managing a large series of Chinese patients with primary nasal lymphoma.
  
  
  METHODS
  From January 1975 to December 1993, 100 patients (median age, 50 years) with newly diagnosed primary nasal lymphoma were studied. There were four low-grade, 62 intermediate-grade, nine high-grade, and 25 unclassifiable lymphomas. Immunophenotyping was performed in 45 patients: eight B cell, 35 T cell, and two uncertain. All cases of angiocentric lymphoma that were typed were T cell. Fifty-two patients had stage I disease, 15 had stage II, four had stage III, and 29 had stage IV. Only 15 patients had B symptoms (weight loss, night sweats, and/or fever), and 11 had bulky disease. Thirty-nine patients with clinically localized stage I and II disease received local radiotherapy alone (before 1980), and the remaining 28 stage I and II patients received combination chemotherapy followed by local radiotherapy. The 33 patients with advanced stage III and IV disease were given combination chemotherapy, and additional radiotherapy was given to five of them who had bulky local disease.
  
  
  RESULTS
  Significantly higher complete remission rates were observed in patients with early stages of disease and those without B symptoms. Superior disease-free survival after complete remission was observed in patients with stage I/II disease. Univariate factors associated with a better overall survival included age less than 60 years, stage I disease, and absence of B symptoms. Survival was significantly better in the subgroup of patients with stage I disease.
  
  
  CONCLUSIONS
  Patients with nasal lymphoma, especially those with advanced disease, seemed to have a poor prognosis, and their clinical outcome was not improved significantly by the use of chemotherapy instead of radiotherapy or the use of doxorubicin-containing chemotherapeutic regimens.
authors.affiliation: Department of Medicine, Queen Mary Hospital, University of Hong Kong, Pokfulam.
authors.forename: R
authors.initials: R
authors.lastname: Liang
authors.forename: D
authors.initials: D
authors.lastname: Todd
authors.forename: T K
authors.initials: TK
authors.lastname: Chan
authors.forename: E
authors.initials: E
authors.lastname: Chiu
authors.forename: A
authors.initials: A
authors.lastname: Lie
authors.forename: Y L
authors.initials: YL
authors.lastname: Kwong
authors.forename: D
authors.initials: D
authors.lastname: Choy
authors.forename: F C
authors.initials: FC
authors.lastname: Ho
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D009669:Nose Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D012044:Regression Analysis; D012074:Remission Induction; D015996:Survival Rate; D016896:Treatment Outcome